{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:52:40Z","timestamp":1792000360025,"version":"4.4.0"},"reference-count":126,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UID\/DTP\/04138\/2019"],"award-info":[{"award-number":["UID\/DTP\/04138\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["CEECINST\/00145\/2018"],"award-info":[{"award-number":["CEECINST\/00145\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The use of natural products in dermatology is increasingly being pursued due to sustainability and ecological issues, and as a possible way to improve the therapeutic outcome of chronic skin diseases, relieving the burden for both patients and healthcare systems. The legalization of cannabis by a growing number of countries has opened the way for researching the use of cannabinoids in therapeutic topical formulations. Cannabinoids are a diverse class of pharmacologically active compounds produced by Cannabis sativa (phytocannabinoids) and similar molecules (endocannabinoids, synthetic cannabinoids). Humans possess an endocannabinoid system involved in the regulation of several physiological processes, which includes naturally-produced endocannabinoids, and proteins involved in their transport, synthesis and degradation. The modulation of the endocannabinoid system is a promising therapeutic target for multiple diseases, including vascular, mental and neurodegenerative disorders. However, due to the complex nature of this system and its crosstalk with other biological systems, the development of novel target drugs is an ongoing challenging task. The discovery of a skin endocannabinoid system and its role in maintaining skin homeostasis, alongside the anti-inflammatory actions of cannabinoids, has raised interest in their use for the treatment of skin inflammatory diseases, which is the focus of this review. Oral treatments are only effective at high doses, having considerable adverse effects; thus, research into plant-based or synthetic cannabinoids that can be incorporated into high-quality, safe topical products for the treatment of inflammatory skin conditions is timely. Previous studies revealed that such products are usually well tolerated and showed promising results for example in the treatment of atopic dermatitis, psoriasis, and contact dermatitis. However, further controlled human clinical trials are needed to fully unravel the potential of these compounds, and the possible side effects associated with their topical use.<\/jats:p>","DOI":"10.3390\/ph15020210","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T21:22:15Z","timestamp":1644441735000},"page":"210","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4822-3249","authenticated-orcid":false,"given":"Ana M.","family":"Martins","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Gomes","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Vilas Boas","sequence":"additional","affiliation":[{"name":"Faculdade de Farm\u00e1cia, Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-5622","authenticated-orcid":false,"given":"Joana","family":"Marto","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-7991","authenticated-orcid":false,"given":"Helena M.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003 Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"ref_1","unstructured":"Villena, K. (2021, April 21). Dermocosmetics: The Junction of Skin Care and Health and Wellness. Available online: https:\/\/blog.euromonitor.com\/dermocosmetics-the-junction-of-skin-care-and-health-and-wellness\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Amberg, N., and Fogarassy, C. (2019). Green Consumer Behavior in the Cosmetics Market. Resources, 8.","DOI":"10.3390\/resources8030137"},{"key":"ref_3","unstructured":"Villena, K. (2021, April 21). Winning with Cannabis in Beauty and Personal Care: How to Identify Areas of Opportunity. Available online: https:\/\/blog.euromonitor.com\/winning-with-cannabis-in-beauty-and-personal-care-how-to-identify-areas-of-opportunity\/."},{"key":"ref_4","unstructured":"Preedy, V.R. (2017). The Cannabis plant: Botanical aspects. Handbook of Cannabis and Related Pathologies, Elsevier Inc."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Brown, D.T. (1998). The Cannabis Plant: Botany, Cultivation and Processing for Use. Cannabis: The Genus Cannabis, CRC Press. Chapter 2.","DOI":"10.4324\/9780203304228"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jep.2018.09.004","article-title":"Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history","volume":"227","author":"Bonini","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1017\/S0003598X0008368X","article-title":"Upper Palaeolithic fibre technology: Interlaced woven finds from Pavlov I, Czech Republic, c. 26,000 years ago","volume":"70","author":"Adovasio","year":"1996","journal-title":"Antiquity"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cherney, J.H., and Small, E. (2016). Industrial hemp in North America: Production, politics and potential. Agronomy, 6.","DOI":"10.3390\/agronomy6040058"},{"key":"#cr-split#-ref_9.1","unstructured":"EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Turck, D., Bresson, J.-L., Burlingame, B., Dean, T., Fairweather-Tait, S., Heinonen, M., Hirsch-Ernst, K.I., Mangelsdorf, I., and McArdle, H. (2016). Guidance on the preparation and presentation of an application for authorisation of a novel food in the context of Regulation"},{"key":"#cr-split#-ref_9.2","unstructured":"(EU) 2015\/2283. EFSA J., 14, e04594."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000489287","article-title":"The Trouble with CBD Oil","volume":"1","author":"Hazekamp","year":"2018","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J175v02n02_01","article-title":"Introduction: Women and cannabis: Medicine, science, and sociology","volume":"2","author":"Russo","year":"2002","journal-title":"J. Cannabis Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejmech.2018.07.076","article-title":"Medicinal properties of terpenes found in Cannabis sativa and Humulus lupulus","volume":"157","author":"Nuutinen","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Scheau, C., Badarau, I.A., Mihai, L.-G., Scheau, A.-E., Costache, D.O., Constantin, C., Calina, D., Caruntu, C., Costache, R.S., and Caruntu, A. (2020). Cannabinoids in the pathophysiology of skin inflammation. Molecules, 25.","DOI":"10.3390\/molecules25030652"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gon\u00e7alves, J., Rosado, T., Soares, S., Sim\u00e3o, A.Y., Caramelo, D., Lu\u00eds, \u00c2., Fern\u00e1ndez, N., Barroso, M., Gallardo, E., and Duarte, A.P. (2019). Cannabis and its secondary metabolites: Their use as therapeutic drugs, toxicological aspects, and analytical determination. Medicines, 6.","DOI":"10.3390\/medicines6010031"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13030\/qt7pn8c0sb","DOI":"10.5070\/D3246040706","article-title":"Cannabinoids in dermatology: A scoping review","volume":"24","author":"Eagleston","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_16","first-page":"1","article-title":"Phytochemistry of Cannabis sativa L.","volume":"103","author":"ElSohly","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., and Dosio, F. (2018). Cannabinoid delivery systems for pain and inflammation treatment. Molecules, 23.","DOI":"10.3390\/molecules23102478"},{"key":"ref_18","unstructured":"Small, E. (2016). Cannabis: A Complete Guide, CRC Press. [1st ed.]."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s42003-020-01530-y","article-title":"The antimicrobial potential of cannabidiol","volume":"4","author":"Blaskovich","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Atalay, S., Jarocka-Karpowicz, I., and Skrzydlewska, E. (2019). Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants, 9.","DOI":"10.3390\/antiox9010021"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ebiom.2017.01.003","article-title":"Targeting Cutaneous cannabinoid signaling in inflammation\u2014A \u201chigh\u201d-way to heal?","volume":"16","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s42238-021-00062-4","article-title":"The biosynthesis of the cannabinoids","volume":"3","author":"Tahir","year":"2021","journal-title":"J. Cannabis Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.febslet.2007.05.043","article-title":"Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa","volume":"581","author":"Taura","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17411","DOI":"10.1074\/jbc.271.29.17411","article-title":"Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid","volume":"271","author":"Taura","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1600-0625.2009.00923.x","article-title":"Cannabinoid system in the skin\u2014A possible target for future therapies in dermatology","volume":"18","author":"Kupczyk","year":"2009","journal-title":"Exp. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/CCID.S286411","article-title":"Therapeutic potential of cannabidiol (CBD) for skin health and disorders","volume":"13","author":"Baswan","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40261-020-00894-7","article-title":"Mechanisms of cannabinoids and potential applicability to skin diseases","volume":"40","author":"Cintosun","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bjp.2008.324","article-title":"\u2018Entourage\u2019 effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors","volume":"155","author":"Ho","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/092986710790980014","article-title":"From surface to nuclear receptors: The endocannabinoid family extends its assets","volume":"17","author":"Pistis","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/DER.0000000000000257","article-title":"The endocannabinoid system and its role in eczematous dermatoses","volume":"28","author":"Trusler","year":"2017","journal-title":"Dermatitis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.4049\/jimmunol.1500546","article-title":"Anandamide suppresses proinflammatory T cell responses in vitro through type-1 cannabinoid receptor-mediated mTOR inhibition in human keratinocytes","volume":"197","author":"Rapino","year":"2016","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Stasiulewicz, A., Znajdek, K., Grudzie\u0144, M., Pawi\u0144ski, T., and Sulkowska, A.J.I. (2020). A guide to targeting the endocannabinoid system in drug design. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082778"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.tins.2011.03.003","article-title":"Supply and demand for endocannabinoids","volume":"34","author":"Alger","year":"2011","journal-title":"Trends Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fnmol.2017.00166","article-title":"Metabolism of the endocannabinoid anandamide: Open questions after 25 years","volume":"10","author":"Maccarrone","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/092986607780090829","article-title":"Critical enzymes involved in endocannabinoid metabolism","volume":"14","author":"Basavarajappa","year":"2007","journal-title":"Protein Pept. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2018.05.002","article-title":"2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain","volume":"71","author":"Baggelaar","year":"2018","journal-title":"Prog. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Martins, A.M., Ascenso, A., Ribeiro, H.M., and Marto, J. (2020). The brain-skin connection and the pathogenesis of psoriasis: A review with a focus on the serotonergic system. Cells, 9.","DOI":"10.3390\/cells9040796"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/09546634.2019.1675854","article-title":"The potential role of cannabinoids in dermatology","volume":"31","author":"Sheriff","year":"2020","journal-title":"J. Dermatolog. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jeong, S., Kim, M.S., Lee, S.H., and Park, B.D. (2019). Epidermal endocannabinoid system (EES) and its cosmetic application. Cosmetics, 6.","DOI":"10.3390\/cosmetics6020033"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/jid.2015.41","article-title":"Distribution of bioactive lipid mediators in human skin","volume":"135","author":"Kendall","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"T\u00f3th, K.F., \u00c1d\u00e1m, D., B\u00edr\u00f3, T., and Ol\u00e1h, A. (2019). Cannabinoid signaling in the skin: Therapeutic potential of the \u201cC(ut)annabinoid\u201d system. Molecules, 24.","DOI":"10.3390\/molecules24050918"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bcp.2018.08.022","article-title":"The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders","volume":"157","author":"Appendino","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jdermsci.2015.11.005","article-title":"The cross-talk between electrophiles, antioxidant defence and the endocannabinoid system in fibroblasts and keratinocytes after UVA and UVB irradiation","volume":"81","author":"Biernacki","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1126\/science.1142265","article-title":"Attenuation of allergic contact dermatitis through the endocannabinoid system","volume":"316","author":"Karsak","year":"2007","journal-title":"Science"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/cmdc.200700168","article-title":"Allergic contact dermatitis and the endocannabinoid system: From mechanisms to skin care","volume":"2","author":"Lambert","year":"2007","journal-title":"ChemMedChem"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2005.01.007","article-title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin","volume":"38","author":"Schmelz","year":"2005","journal-title":"J. Dermatol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Muller, C., Morales, P., and Reggio, P.H. (2019). Cannabinoid Ligands Targeting TRP Channels. Front. Mol. Neurosci., 11.","DOI":"10.3389\/fnmol.2018.00487"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/cosmetics8030085","article-title":"Topical Use of Cannabis sativa L. Biochemicals","volume":"8","author":"Mnekin","year":"2021","journal-title":"Cosmetics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaad.2017.02.056","article-title":"The role of cannabinoids in dermatology","volume":"77","author":"Mounessa","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.tips.2009.05.004","article-title":"The endocannabinoid system of the skin in health and disease: Novel perspectives and therapeutic opportunities","volume":"30","author":"Paus","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10681-004-4811-6","article-title":"Hempseed as a nutritional resource: An overview","volume":"140","author":"Callaway","year":"2004","journal-title":"Euphytica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40257-017-0301-1","article-title":"Natural oils for skin-barrier repair: Ancient compounds now backed by modern science","volume":"19","author":"Vaughn","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_53","unstructured":"Moreau, R., and Kamal-Eldin, A. (2009). Hempseed oil. Gourmet and Health-Promoting Specialty Oils, AOCS Press."},{"key":"ref_54","first-page":"68","article-title":"Stirring the pot: Cannabinoids and AD","volume":"15","author":"Shalaby","year":"2018","journal-title":"Pract. Dermatol. Online J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/can.2019.0097","article-title":"Cannabinoids in dermatology: Hope or hype?","volume":"5","author":"Nickles","year":"2020","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_56","first-page":"97","article-title":"Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: A preliminary study","volume":"13","author":"Szepietowski","year":"2005","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_57","first-page":"801","article-title":"Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus","volume":"57","author":"Reinhardt","year":"2006","journal-title":"Hautarzt"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12974-015-0273-0","article-title":"Cannabidiol, a non-psychoactive cannabinoid, leads to EGR2-dependent anergy in activated encephalitogenic T cells","volume":"12","author":"Kozela","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pertwee, R.G. (2005). Pharmacokinetics and metabolism of the plant cannabinoids, \u03949-tetrahydrocannibinol, cannabidiol and cannabinol. Cannabinoids, Springer.","DOI":"10.1007\/b137831"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1515\/cclm-2017-0758","article-title":"Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry","volume":"56","author":"Pacifici","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1096\/fj.07-104877","article-title":"Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling","volume":"22","author":"Dobrosi","year":"2008","journal-title":"FASEB J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1172\/JCI64628","article-title":"Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes","volume":"124","author":"Sugawara","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_65","first-page":"1389","article-title":"The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content","volume":"28","author":"Ali","year":"2015","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/exd.12930","article-title":"Inhibition of fatty acid amide hydrolase exerts cutaneous anti-inflammatory effects both in vitro and in vivo","volume":"25","author":"Ambrus","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Jin, S., and Lee, M.Y. (2018). The ameliorative effect of hemp seed hexane extracts on the Propionibacterium acnes-induced inflammation and lipogenesis in sebocytes. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202933"},{"key":"ref_68","unstructured":"Botanix Pharmaceuticals (2019). ASX\/Media Release: BTX 1503 Acne Phase 2 Study Results Presentation, Botanix Pharmaceuticals. Available online: https:\/\/www.asx.com.au\/asxpdf\/20191023\/pdf\/449s36d2bz6vfr.pdf."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejphar.2005.08.013","article-title":"Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice","volume":"520","author":"Ueda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.4049\/jimmunol.177.12.8796","article-title":"Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice","volume":"177","author":"Oka","year":"2006","journal-title":"J. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1398-9995.2009.02254.x","article-title":"Protective role of palmitoylethanolamide in contact allergic dermatitis","volume":"65","author":"Petrosino","year":"2010","journal-title":"Allergy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/all.12183","article-title":"Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors","volume":"68","author":"Gaffal","year":"2013","journal-title":"Allergy"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.117.244368","article-title":"Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis","volume":"365","author":"Petrosino","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: Results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/exd.12414","article-title":"Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis","volume":"23","author":"Gaffal","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1111\/ijd.12841","article-title":"Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model","volume":"54","author":"Kim","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5021\/ad.2016.28.1.22","article-title":"Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model","volume":"28","author":"Nam","year":"2016","journal-title":"Ann. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09546630510035832","article-title":"Efficacy of dietary hempseed oil in patients with atopic dermatitis","volume":"16","author":"Callaway","year":"2005","journal-title":"J. Dermatolog. Treat."},{"key":"ref_79","first-page":"208","article-title":"Use of a palmitoylethanolamide-containing nonsteroidal cream for treating atopic dermatitis: Impact on the duration of response and time between flares","volume":"20","year":"2007","journal-title":"Cosmet. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1468-3083.2007.02351.x","article-title":"Adjuvant treatment of atopic eczema: Assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)","volume":"22","author":"Eberlein","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Metwally, S., Ura, D.P., Krysiak, Z.J., Kaniuk, \u0141., Szewczyk, P.K., and Stachewicz, U. (2021). Electrospun PCL patches with controlled fiber morphology and mechanical performance for skin moisturization via long-term release of hemp oil for atopic dermatitis. Membranes, 11.","DOI":"10.3390\/membranes11010026"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00011-003-1162-z","article-title":"Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin","volume":"52","author":"Dvorak","year":"2003","journal-title":"Inflamm. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2340\/00015555-2593","article-title":"Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: A dermatocosmetic study","volume":"97","author":"Visse","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jdermsci.2006.10.009","article-title":"Cannabinoids inhibit human keratinocyte proliferation through a non-CB1\/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis","volume":"45","author":"Wilkinson","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.7717\/peerj.40","article-title":"A novel control of human keratin expression: Cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ","volume":"1","author":"Ramot","year":"2013","journal-title":"PeerJ"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mehy.2016.12.003","article-title":"Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation","volume":"99","author":"Norooznezhad","year":"2017","journal-title":"Med. Hypotheses"},{"key":"ref_87","unstructured":"Changoer, L., and Anastassov, G. Method to Treat Psoriasis. Patent 20190060250, 28 February 2019, AXIM Biotechnologies, Inc.. Available online: https:\/\/www.freepatentsonline.com\/y2019\/0060250.html."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"795","DOI":"10.36849\/JDD.2020.5229","article-title":"Topical cannabinoids for the management of psoriasis vulgaris: Report of a case and review of the literature","volume":"19","author":"Friedman","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/jdv.12298","article-title":"Acne is an inflammatory disease and alterations of sebum composition initiate acne lesions","volume":"28","author":"Zouboulis","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12026-011-8210-5","article-title":"Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease","volume":"51","author":"Basu","year":"2011","journal-title":"Immunol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nri3150","article-title":"Early immune events in the induction of allergic contact dermatitis","volume":"12","author":"Kaplan","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/DER.0000000000000378","article-title":"Contact Buzz: Allergic Contact Dermatitis to Cannabis","volume":"29","author":"Foster","year":"2018","journal-title":"Dermatitis"},{"key":"ref_93","unstructured":"Specht, S., and Persaud, Y. (2021, July 21). Asteatotic Eczema, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549807\/."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/mol.104.006353","article-title":"The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide","volume":"67","author":"Fu","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"ref_95","first-page":"81","article-title":"A narrative review of psoriasis and multiple sclerosis: Links and risks","volume":"9","author":"Homan","year":"2019","journal-title":"Psoriasis"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Azevedo Martins, T.E., Sales de Oliveira Pinto, C.A., Costa de Oliveira, A., Robles Velasco, M.V., Gorriti Guiti\u00e9rrez, A.R., Cosquillo Rafael, M.F., Tarazona, J.P.H., and Retuerto-Figueroa, M.G. (2020). Contribution of topical antioxidants to maintain healthy skin\u2014A review. Sci. Pharm., 88.","DOI":"10.3390\/scipharm88020027"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"a015354","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Villanova","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1468-3083.2004.01184.x","article-title":"Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition","volume":"19","author":"Namazi","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/1574884711666160511150126","article-title":"Cannabis for refractory psoriasis\u2014High hopes for a novel treatment and a literature review","volume":"11","author":"Derakhshan","year":"2016","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"74236","DOI":"10.18632\/oncotarget.12371","article-title":"Overexpression and potential roles of NRIP1 in psoriasis","volume":"7","author":"Luan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1007\/s12035-020-01889-3","article-title":"Current and future therapies for psoriasis with a focus on serotonergic drugs","volume":"57","author":"Martins","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/jpet.108.150136","article-title":"Endocannabinoid modulation of scratching response in an acute allergenic model: A new prospective neural therapeutic target for pruritus","volume":"329","author":"Schlosburg","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: A review","volume":"82","author":"Avila","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","first-page":"51","article-title":"FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels","volume":"11","author":"Petrosino","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00403-016-1649-4","article-title":"Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH\/MAGL inhibitors produce antipruritic effect in mice","volume":"308","author":"Yesilyurt","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Cohen, K., and Weinstein, A. (2018). The effects of cannabinoids on executive functions: Evidence from cannabis and synthetic cannabinoids-a systematic review. Brain Sci., 8.","DOI":"10.3390\/brainsci8030040"},{"key":"ref_107","unstructured":"EMCDDA (2018). Cannabis Legislation in Europe. An Overview, European Monitoring Centre for Drugs and Drug Addiction. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/4135\/TD0217210ENN.pdf."},{"key":"ref_108","unstructured":"UNODC (2013). The International Drug Control Conventions, United Nations Office on Drugs and Crime. Available online: https:\/\/www.unodc.org\/documents\/commissions\/CND\/Int_Drug_Control_Conventions\/Ebook\/The_International_Drug_Control_Conventions_E.pdf."},{"key":"ref_109","unstructured":"United Nations (2021, September 10). Single Convention on Narcotic Drugs, Available online: https:\/\/www.incb.org\/documents\/Narcotic-Drugs\/1961-Convention\/convention_1961_en.pdf."},{"key":"ref_110","unstructured":"EMCDDA (2019). Developments in the European Cannabis Market, European Monitoring Centre for Drugs and Drug Addiction. Available online: https:\/\/www.emcdda.europa.eu\/publications\/emcdda-papers\/developments-in-the-european-cannabis-market_en."},{"key":"ref_111","unstructured":"WHO (2021, September 10). The WHO Expert Committee on Drug Dependence (ECDD), Available online: https:\/\/www.who.int\/groups\/who-expert-committee-on-drug-dependence."},{"key":"ref_112","unstructured":"WHO (2021, September 10). Cannabidiol (CBD) Critical Review Report, Available online: https:\/\/www.who.int\/medicines\/access\/controlled-substances\/CannabidiolCriticalReview.pdf."},{"key":"ref_113","unstructured":"NCSL (2021). State Medical Marijuana Laws, National Conference of State Legislators. Available online: https:\/\/www.ncsl.org\/research\/health\/state-medical-marijuana-laws.aspx."},{"key":"ref_114","unstructured":"Pascual, A., and Medical Cannabis in Europe: The Markets  Opportunities (2021, September 10). Marijuana Business Daily International. Available online: https:\/\/mjbizdaily.com\/wp-content\/uploads\/2019\/04\/Medical-Cannabis-in-Europe-Report_FINAL_REV2.pdf."},{"key":"ref_115","unstructured":"FDA (2021, September 02). FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD), Available online: https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd."},{"key":"ref_116","unstructured":"FDA (2021, September 30). Epidiolex\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210365lbl.pdf."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","article-title":"Medical use of cannabis and cannabinoids containing products\u2014Regulations in Europe and North America","volume":"49","author":"Abuhasira","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"ref_118","unstructured":"EMCDDA (2018). Medical Use of Cannabis and Cannabinoids: Questions and Answers for Policymaking, European Monitoring Centre for Drugs and Drug Addiction. Available online: https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/10171\/20185584_TD0618186ENN_PDF.pdf."},{"key":"ref_119","unstructured":"(2021, September 30). Bedrocan. Available online: https:\/\/bedrocan.com\/."},{"key":"ref_120","unstructured":"EMCDDA (2018). European Drug Report 2018: Trends and Developments, European Monitoring Centre for Drugs and Drug Addiction. Available online: http:\/\/www.emcdda.europa.eu\/publications\/edr\/trends-developments\/2018."},{"key":"ref_121","unstructured":"EMA (2021, September 30). Epidyolex (cannabidiol). An Overview of Epidyolex and Why it is Authorised in the EU, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/epidyolex-epar-medicine-overview_en.pdf."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1203475418808761","article-title":"Dermatology-related uses of medical cannabis promoted by dispensaries in Canada, Europe, and the United States","volume":"23","author":"Lim","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2019.03.015","article-title":"Allergenic ingredients in commercial topical cannabinoid preparations","volume":"81","author":"Adler","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s13063-020-04862-6","article-title":"Clinical trials with cannabis medicines\u2014guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: Considerations from the Australian experience","volume":"21","author":"Martin","year":"2020","journal-title":"Trials"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.drugpo.2019.03.006","article-title":"Cannabis use in Europe: Current trends and public health concerns","volume":"68","author":"Manthey","year":"2019","journal-title":"Int. J. Drug Policy"}],"updated-by":[{"DOI":"10.3390\/ph15070849","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000}}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/2\/210\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T13:58:28Z","timestamp":1754229508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/2\/210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":126,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ph15020210"],"URL":"https:\/\/doi.org\/10.3390\/ph15020210","relation":{"correction":[{"id-type":"doi","id":"10.3390\/ph15070849","asserted-by":"object"}]},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]}}}